Zopiclone is a poorly soluble psychotherapeutic agent. The aim of this study was to prepare and characterize an amorphous form of zopiclone as well as the characterization and performance of a stable amorphous solid dispersion. The amorphous form was prepared by the well-known method of quench-cooling of the melt. The solid dispersion was prepared by a solvent evaporation method of zopiclone, polyvinylpyrrolidone-25 (PVP-25), and methanol, followed by freeze-drying. The physico-chemical properties and stability of amorphous zopiclone and the solid dispersion was studied using differential scanning calorimetry (DSC), infrared spectroscopy (FT-IR), thermogravimetric analysis (TGA), scanning electron microscopy (SEM), hot-stage microscopy (HSM), X-ray diffractometry (XRD), solubility, and dissolution studies. The zopiclone amorphous solid-state form was determined to be a fragile glass; it was concluded that the stability of the amorphous form is influenced by both temperature and water. Exposure of amorphous zopiclone to moisture results in rapid transformation of the amorphous form to the crystalline dihydrated form. In comparison, the amorphous solid dispersion proved to be more stable with increased aqueous solubility.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Dollery C. Therapeutic drugs, second edition. Edinburgh: Churchill Livingstone. 1999; 194–198.
Dundar Y, Boland A, Strobl J, Dodd S, Haycox A, Bagust A, et al. Newer hypnotic drugs for the short term management of insomnia: a systematic review and economic evaluation. Health Technol Assessment Pubmed Health. 2004;8(24):1–140.
British Pharmacopoeia 2014. http://www.pharmacopoeia.co.uk.nwulib.nwu.ac.za/bp2014/ixbin/bp.cgi. Accessed 20 Aug 2014.
Shankland N, David WIF, Shankland K, Kennedy AR, Frampton CS, Florence AJ. Structural transformations in zopiclone. Chem Commun. 2001;21:2204–5.
Terblanche RJ, Liebenberg W, de Villiers MM. Characterization of zopiclone crystal forms found among generic raw materials. Drug Dev Ind Pharm. 2000;26(5):531–7.
Aulton ME, Taylor K. Aulton’s pharmaceutics: the design and manufacture of medicines. 4th ed. Spain: Harcourt Publishers Limited; 2013. p. 26–239. 145–148.
Hancock BC, Parks M. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res. 2000;17:379–404.
Aucamp M, Liebenberg W, Strydom SJ, van Tonder EC, de Villiers MM. Physiochemical properties of amorphous roxithromycin prepared by quench cooling of the melt or desolvation of a chloroform solvate. AAPS PharmSciTech. 2012;13(2):467–76.
Hancock BC, Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci. 1997;86(1):1–12.
Byrn SR, Pfeiffer RR, Stowel JG. Solid-state chemistry of drugs. 2nd ed. West Lafayette: SSCI Inc; 1999. 573p.
Brougha C, Williams RO. Amorphous solid dispersions and nano-crystal technologies for poorly water-soluble drug delivery. Int. J. Pharm. 2013; 157–167.
Huang Y, Daib W. Fundamental aspects of solid dispersion technology for poorly soluble drugs. APSB. 2013; 18–25.
Wang X, Michoel A, Van den Mooter G. Solid-state characteristics of ternary solid dispersions composed of PVP VA64, Myrj 52 and itraconazole. Int J Pharm. 2005;303:54–61.
Terblanche RJ. Crystal transformations of the cyclopyrrolone zopiclone a non-benzodiazepine sedative and hypnotic drug. Potchefstroom: NWU. (Thesis – MSc). 1999.
Terblanche RJ. Thermo-mechanical transformation of drug polymorphs and pseudopolynorphs characterised by differential scanning calorimetry and X-ray powder diffraction. PhD thesis, Potchefstroom: NWU. 2001.
Paw B, Misztal G. Determination of zopiclone in tablets by HPLC and UV-spectrophotometry. J Pharm Biomed. 2000;23:819–23.
Greco K, Bogner R. Solution-mediated phase transformation: significance during dissolution and implications for bioavailability. J Pharm Sci. 2012;101:2996–3018.
Senkov ON. Correlation between fragility and glass forming ability of metallic alloys. Phys Rev B. 2007;76:104202-1–6.
Kawakami K. Dynamics of ribavirin glass in sub-Tg temperature region. J PhysChem B. 2011;115:11375–81.
Crowley KJ, Zografi G. The use of thermal methods for predicting glass-former fragility. Thermochim Acta. 2001;380:79–93.
Baird JA, van Eerdenbrugh B, Taylor LS. A classification system to assess the crystallization tendency of organic molecules from undercooled melts. J Pharm Sci. 2010;99:3787–806.
Kawakami K, Usui T, Hattori M. Understanding the glass-forming ability of active pharmaceutical ingredients for designing supersaturating dosage forms. J Pharm Sci. 2012;3239–3248.
Li Y, Han J, Zhang GGZ, Grant DJW, Suryanarayanan R. In situ dehydration of carbamazepine dehydrate: a novel technique to prepare amorphous anhydrous carbamazepine. Pharm Dev Tech. 2000;5(2):257–66.
Angell CA. Why C1 = 16–17 in the WLF equation is physical—and the fragility of polymers. Polym. 1997;38(26):6261–6.
Bohmer R, Angell CA. Correlations of the non-exponentially and state dependence of mechanical relaxations with bond connectivity in germanium-arsenic-selenium supercooled liquids. Phys Rev B. 1992;45(17):10091–4.
Angell, CA, Alba, C, Arzmanoglou, A, Bohmer, R, Fan, J, Lu, Q, Sanchez, E, Senapati, H, Tatsumisago, M. Slow processes in viscous liquids: stress and structural relaxation, chemical reaction freezing, crystal nucleation and microemulsion arrest, in relation to liquid fragility. Am. Inst. Phys. Conf. Proc. 992; (256): 1; 3–19.
Lu Q, Zografi G. Properties of citric acid at the glass transition. J Pharm Sci. 1997;86(12):1374–8.
Borea PA, Gilli G, Bertolasi V, Ferretti V. Streochemical feuters controlling binding and intrinsic activity properties of benzodiazepine-receptor ligands. Mol Pharm. 1987;31:334–44.
Flory PJ. Principles of polymer chemistry. Ithaca: Cornell University Press; 1953.
Marsac PJ, Li T, Taylor LS. Estimation of drug-polymer miscibility and solubility in amorphous solid dispersions using experimentally determined interaction parameters. Pharm Res. 2009;26(1):139–51.
Bertolasie V, Feretti V, Gilli G. Stereochemistry of benzodiazepine receptor ligands: possible role of C–H···x interactions in drug-receptor binding and crystal structures of CL218-872, zopiclone and DMCM. J Chem Soc Perkins Trans. 1990;2:283–9.
Aucamp ME, Stieger N, Barnard N, Liebenberg W. Solution-mediated phase transformation of different roxithromycin solid-state forms: Implications on dissolution and solubility. Int J Pharm. 2013;449:18–27.
The authors are grateful to the North-West University, South Africa (Potchefstroom Campus as well as the National Research Foundation (NRF) of South Africa for research support.
Any opinion, findings, and conclusions or recommendations expressed in this material are those of the authors and therefore the NRF do not accept any liability thereto.
Rights and permissions
About this article
Cite this article
Milne, M., Liebenberg, W. & Aucamp, M. The Stabilization of Amorphous Zopiclone in an Amorphous Solid Dispersion. AAPS PharmSciTech 16, 1190–1202 (2015). https://doi.org/10.1208/s12249-015-0302-4
- solid dispersion